

bs-1502R**[Primary Antibody]****CXCL10/IP10 Rabbit pAb****Bioss**
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn


400-901-9800

— DATASHEET —


Host: Rabbit	Isotype: IgG	Applications: IHC-P (1:100-500)
Clonality: Polyclonal		IHC-F (1:100-500)
GeneID: 15945	SWISS: P17515	IF (1:100-500)
Target: CXCL10/IP10		Flow-Cyt (1 μ g/Test)
Immunogen: KLH conjugated synthetic peptide derived from mouse CXCL10: 35-98/98.		Reactivity: Human, Mouse, Rat
Purification: affinity purified by Protein A		
Concentration: 1mg/ml		Predicted MW.: 10 kDa
Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		Subcellular Location: Secreted
Background: bs-1502P is one synthetic peptide derived from mouse CXCL10. Interferon-gamma-inducible 10 kD protein (IP-10), is a CXC chemokine with chemoattractant properties for CD4-positive T cells and inhibits early normal and leukemic hemopoietic progenitor proliferation. IP-10 is produced by a wide variety of cell types ranging from neutrophils and monocytes to hepatocytes, endothelial cells and keratinocytes. The cytokine is reported to be involved in a scale of inflammatory pathologies such as HIV encephalitis, cutaneous T cell lymphoma, chronic hepatitis and acute anterior uveitis. Various observations strongly suggest a role for the CXC chemokines IL-8 and IP-10 in the regulation of angiogenic activity in cancer and in idiopathic pulmonary fibrosis.		

— VALIDATION IMAGES —


Tissue/cell: rat lung tissue; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Incubation: Anti-CXCL10 Polyclonal Antibody, Unconjugated (bs-1502R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody (SP-0023) and DAB (C-0010) staining



C57BL/6 mice skin were fixed in pre-chilled MeOH and incubated at -20°C for 10 minutes. They were washed in PBS at RT 3 times for 5 minutes each. The sections were blocked for 60 minutes at RT with PBS containing 5% BSA. The block was removed, anti-CXCL10 antibody (bs-1502R) diluted 1:50 was added, then incubated overnight at 4°C. Then washed with PBS (0.005% Tween20) for 15 minutes each followed by 2 washes of PBS for 5 minutes each. The secondary antibody, anti-rabbit A488 was diluted 1:500, added to the sections and incubated for 1 hour at RT. Then washed for 10 minutes in PBS 4 times



Blank control: Raw264.7. Primary Antibody (green line): Rabbit Anti-CXCL10/IP10 antibody (bs-1502R) Dilution: 1 μ g /10⁶ cells; Isotype Control Antibody (orange line): Rabbit IgG. Secondary Antibody: Goat anti-rabbit IgG-AF647 Dilution: 1 μ g /test. Protocol The cells were fixed with 4% PFA (10min at room temperature) and then permeabilized with 0.1% PBST for 20 min at room temperature. The cells were then incubated in 5% BSA to block non-specific protein-protein interactions for 30 min at room temperature. Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.



Blank control: Raw264.7. Primary Antibody (green line): Rabbit Anti-CXCL10/IP10 antibody (bs-1502R) Dilution: 1 μ g /10⁶ cells; Isotype Control Antibody (orange line): Rabbit IgG . Secondary Antibody : Goat anti-rabbit IgG-AF647 Dilution: 1 μ g /test. Protocol The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 0.1% PBST for 20 min at room temperature.The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

— SELECTED CITATIONS —

- **[IF=21.506]** Iversen, Marie B., et al. "An innate antiviral pathway acting before interferons at epithelial surfaces." *Nature immunology* (2015). IHC ;Mouse. 26595890
- **[IF=16.6]** Maeda Rae. et al. Amino acid catabolite markers for early prognostication of pneumonia in patients with COVID-19. *NAT COMMUN.* 2023 Dec;14(1):1-17 IF ;Human. 38123556
- **[IF=15.584]** Wuchang Zhang. et al. Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress. *Mol Cell.* 2021 Mar;; IF ;Mouse. 33743195
- **[IF=13.6]** Fan Xu. et al. CXCL10 secreted by SPRY1-deficient epidermal keratinocytes fuels joint inflammation in psoriatic arthritis via CD14 signaling. *J CLIN INVEST.* 2025 Jun;; IF ;Mouse. 40471688
- **[IF=13.25]** Günther et al. Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. (2015) *J.Clin.Invest.* 125:413-24 IHC ;Human. 25500883